MedTrace Logo

Envafolimab Combined With Endostatin in Recurrent or Metastatic MSS-type Colorectal Cancer

NCT05551247 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-09-22

No results posted yet for this study

Summary

The objective is to investigate the efficacy and safety of envafolimab combined with recombinant human endostatin (endostatin) in the treatment of MSS-type colorectal cancer patients with recurrence or metastasis after failure of second-line standard therapy.

Conditions

  • Colorectal Neoplasms

Interventions

DRUG

Envafolimab

300mg,sc,d3,Q3W;

DRUG

recombinant human endostatin (endostatin)

210mg,civ,d1-3,Q3W

Sponsors & Collaborators

  • First Affiliated Hospital Xi'an Jiaotong University

    lead OTHER

Principal Investigators

  • Enxiao Li · First Affiliated Hospital of Xian Jiaotong University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-15
Primary Completion
2023-06-28
Completion
2024-06-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05551247 on ClinicalTrials.gov